Avenzo turns to Rallybio for path to NASDAQ: Deals Report

With four in-licensed assets moving along in the clinic, San Diego-based Avenzo is finally ready to reach the public markets via a reverse merger accompanied by a $215 million private placement.

Led by Chair, President and CEO Athena Countouriotis, Avenzo Therapeutics Inc. formed quietly in 2022 with the goal of bringing in oncology assets and advancing them. Using the NewCo model — driving global development of assets from biotechs with ties to China — the start-up has built a pipeline via agreements with Allorion Therapeutics Inc., VelaVigo (Shanghai) Ltd. 橙帆医药 and Duality Biotherapeutics Inc. 映恩生物 (HKEX:9606)...